Shandong Boan Biotechnology Co Ltd
HKEX:6955
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
7.62
18.28
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Shandong Boan Biotechnology Co Ltd
Short-Term Debt
Shandong Boan Biotechnology Co Ltd
Short-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Short-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
S
|
Shandong Boan Biotechnology Co Ltd
HKEX:6955
|
Short-Term Debt
ÂĄ117.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Short-Term Debt
ÂĄ4.7B
|
CAGR 3-Years
31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Short-Term Debt
ÂĄ0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Short-Term Debt
ÂĄ173.1m
|
CAGR 3-Years
31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Short-Term Debt
ÂĄ168.4k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Short-Term Debt
ÂĄ3.4B
|
CAGR 3-Years
86%
|
CAGR 5-Years
7%
|
CAGR 10-Years
52%
|
Shandong Boan Biotechnology Co Ltd
Glance View
Shandong Boan Biotechnology Co., Ltd. operates as a biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization. The company is headquartered in Yantai, Shandong and currently employs 631 full-time employees. The company went IPO on 2022-12-30. The firm is engaged in the development, production and commercialisation of therapeutic antibodies, focusing on the therapeutic areas of oncology, metabolism, autoimmunology and ophthalmology. The firm has three main technology platforms: a fully human antibody transgenic mouse and phage display technology platform, a bispecific T-cell Engager technology platform, and an antibody drug coupling (ADC) technology platform. The firm operates mainly in the domestic Chinese market and overseas markets.
See Also
What is Shandong Boan Biotechnology Co Ltd's Short-Term Debt?
Short-Term Debt
117.8m
CNY
Based on the financial report for Dec 31, 2023, Shandong Boan Biotechnology Co Ltd's Short-Term Debt amounts to 117.8m CNY.
What is Shandong Boan Biotechnology Co Ltd's Short-Term Debt growth rate?
Short-Term Debt CAGR 1Y
1 545%
Over the last year, the Short-Term Debt growth was 1 545%.